Helus Pharma, Inc. (HELP)
10.71
-0.20
(-1.83%)
USD |
NASDAQ |
Oct 29, 16:00
10.60
-0.11
(-1.03%)
After-Hours: 20:00
Helus Pharma Enterprise Value : 509.88M for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | 509.88M |
| October 27, 2026 | 485.71M |
| October 26, 2026 | 475.79M |
| October 23, 2026 | 465.25M |
| October 22, 2026 | 484.47M |
| October 21, 2026 | 501.82M |
| October 20, 2026 | 511.74M |
| October 19, 2026 | 496.24M |
| October 16, 2026 | 487.57M |
| October 15, 2026 | 518.56M |
| October 14, 2026 | 477.03M |
| October 13, 2026 | 484.47M |
| October 12, 2026 | 517.32M |
| October 09, 2026 | 565.05M |
| October 08, 2026 | 498.10M |
| October 07, 2026 | 485.09M |
| October 06, 2026 | 500.58M |
| October 05, 2026 | 541.49M |
| October 02, 2026 | 558.85M |
| October 01, 2026 | 571.87M |
| September 30, 2026 | 595.42M |
| September 29, 2026 | 620.83M |
| September 28, 2026 | 614.01M |
| September 25, 2026 | 615.25M |
| September 24, 2026 | 614.01M |
| Date | Value |
|---|---|
| September 23, 2026 | 640.67M |
| September 22, 2026 | 683.44M |
| September 21, 2026 | 680.34M |
| September 18, 2026 | 600.38M |
| September 17, 2026 | 702.65M |
| September 16, 2026 | 668.56M |
| September 15, 2026 | 646.87M |
| September 14, 2026 | 677.24M |
| September 11, 2026 | 637.57M |
| September 10, 2026 | 629.51M |
| September 09, 2026 | 681.58M |
| September 08, 2026 | 601.62M |
| September 04, 2026 | 591.08M |
| September 03, 2026 | 563.19M |
| September 02, 2026 | 574.34M |
| September 01, 2026 | 552.65M |
| August 31, 2026 | 562.57M |
| August 28, 2026 | 588.60M |
| August 27, 2026 | 654.30M |
| August 26, 2026 | 678.48M |
| August 25, 2026 | 700.48M |
| August 24, 2026 | 640.67M |
| August 21, 2026 | 614.01M |
| August 20, 2026 | 606.58M |
| August 19, 2026 | 563.81M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| InMed Pharmaceuticals, Inc. | 6.305M |
| NervGen Pharma Corp. | 98.45M |
| Milestone Pharmaceuticals, Inc. | 65.52M |
| Appili Therapeutics, Inc. | 10.20M |
| Clearmind Medicine, Inc. | -12.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -47.82M |
| Total Expenses (Quarterly) | 47.82M |
| EPS Diluted (Quarterly) | -0.914 |
| Earnings Yield | -39.64% |
| Normalized Earnings Yield | -38.19 |